Craig-Hallum analyst Alex Nowak raised the firm’s price target on Exact Sciences to $55 from $44 and keeps a Hold rating on the shares. The firm notes that a better tone throughout 2022 led to a strong end to the year. Cologuard generated much better volume growth while Precision Oncology was largely in-line with Craig-Hallum’s original estimate.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXAS: